Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

29452 ARTÍCULOS , VIENDO DEL 28006 AL 28020

The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6

Wang H, Nery ESM, Ardayfio P, Khanna R, Svaldi DO, Shcherbinin S, Xu W, Andersen SW, Hauck PM, Brooks DA, Collins EC, Salloway S, Mintun MA, Sims JR.

J Prev Alzheimers Dis. 2025 Sep;12(8):100266. doi: 10.1016/j.tjpad.2025.100266. Epub 2025 Jul 5.

The Role of Magnesium in Depression, Migraine, Alzheimer's Disease, and Cognitive Health: A Comprehensive Review

Varga P, Lehoczki A, Fekete M, Jarecsny T, Kryczyk-Poprawa A, Zábó V, Major D, Fazekas-Pongor V, Csípő T, Varga JT.

Nutrients. 2025 Jul 4;17(13):2216. doi: 10.3390/nu17132216.

Modulation of Cortical and Hippocampal Functional MRI Connectivity Following Transcranial Alternating Current Stimulation in Mild Alzheimer Disease

Wang T, Yan S, Shan Y, Xue H, Xing Y, Bi S, Chen Z, Xi H, Qi Z, Tang Y, Lu J.

Radiology. 2025 Jun;315(3):e241463. doi: 10.1148/radiol.241463.

A randomized clinical trial of low-dose cannabis extract in Alzheimer's disease

Cury RM, da Silva T, Cezar-Dos-Santos F, Fakih YRC, Narvaez KAR, Gouvea MC, Espínola C, Ferreira CF, de Castro WAC, Pamplona FA, Silva EGD, Bicca MA, Nascimento FP.

J Alzheimers Dis. 2025 Dec;108(4):1602-1613. doi: 10.1177/13872877251389608. Epub 2025 Oct 29.

Donanemab exposure-response in early symptomatic Alzheimer's disease

Gueorguieva I, Chow K, Chua L, Shcherbinin S, Zimmer JA, Evans CD, Wang H, Nery ESM, Brooks DA, Sims JR.

Alzheimers Dement. 2025 Jul;21(7):e70491. doi: 10.1002/alz.70491.

Effects of 52 weeks of precuneus rTMS in Alzheimer's disease patients: a randomized trial

Koch G, Casula EP, Bonnì S, Borghi I, Assogna M, Di Lorenzo F, Esposito R, Maiella M, D'Acunto A, Ferraresi M, Mencarelli L, Pezzopane V, Motta C, Santarnecchi E, Bozzali M, Martorana A.

Alzheimers Res Ther. 2025 Apr 2;17(1):69. doi: 10.1186/s13195-025-01709-7.

TRAILBLAZER-ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease

Salloway S, Pain A, Lee E, Papka M, Ferguson MB, Wang H, Hu H, Lu M, Oru E, Ardayfio PA, Hoban DB, Collins EC, Brooks DA, Sims JR.

Alzheimers Dement. 2025 May;21(5):e70293. doi: 10.1002/alz.70293.

Systematic review and meta-analysis of bulk RNAseq studies in human Alzheimer's disease brain tissue

Aguzzoli Heberle B, Fox KL, Lobraico Libermann L, Ronchetti Martins Xavier S, Tarnowski Dallarosa G, Carolina Santos R, Fardo DW, Wendt Viola T, Ebbert MTW.

Alzheimers Dement. 2025 Mar;21(3):e70025. doi: 10.1002/alz.70025.

Clarity AD: Asian regional analysis of a phase III trial of lecanemab in early Alzheimer's disease

Chen C, Katayama S, Lee JH, Lee JY, Nakagawa M, Torii K, Ogawa T, Dash A, Irizarry M, Dhadda S, Kanekiyo M, Hersch S, Iwatsubo T.

J Prev Alzheimers Dis. 2025 May;12(5):100160. doi: 10.1016/j.tjpad.2025.100160. Epub 2025 Apr 5.

Clinical Benefits and Risks of Antiamyloid Antibodies in Sporadic Alzheimer Disease: Systematic Review and Network Meta-Analysis With a Web Application

Jeremic D, Navarro-Lopez JD, Jimenez-Diaz L.

J Med Internet Res. 2025 Apr 7;27:e68454. doi: 10.2196/68454.

Donanemab in preclinical Alzheimer's disease: Screening and baseline data from TRAILBLAZER-ALZ 3

Yaari R, Holdridge KC, Williamson M, Wessels AM, Shcherbinin S, Kotari V, Reiman EM, Tariot PN, Alexander R, Langbaum JB, Sims JR.

Alzheimers Dement. 2025 Sep;21(9):e70662. doi: 10.1002/alz.70662.

Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer's disease: a randomized controlled phase 2a trial

Rash BG, Ramdas KN, Agafonova N, Naioti E, McClain-Moss L, Zainul Z, Varnado B, Peterson K, Brown M, Leal T, Kopcho S, Carballosa R, Patel P, Brody M, Herskowitz B, Fuquay A, Rodriguez S, Jacobson AF, Leon R, Pfeffer M, Schwartzbard JB, Botbyl J, Oliva AA Jr, Hare JM.

Nat Med. 2025 Apr;31(4):1257-1266. doi: 10.1038/s41591-025-03559-0. Epub 2025 Mar 10.

Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction

Wang H, Serap Monkul Nery E, Ardayfio P, Khanna R, Otero Svaldi D, Gueorguieva I, Shcherbinin S, Andersen SW, Hauck PM, Engle SE, Brooks DA, Collins EC, Fox NC, Greenberg SM, Salloway S, Mintun MA, Sims JR.

Alzheimers Dement. 2025 Apr;21(4):e70062. doi: 10.1002/alz.70062.

Long-term safety and efficacy of lecanemab in early Alzheimer's disease: Results from the clarity AD open-label extension study

van Dyck CH, Sperling R, Johnson K, Dhadda S, Kanekiyo M, Li D, Gee M, Hersch S, Irizarry M, Kramer L.

Alzheimers Dement. 2025 Dec;21(12):e70905. doi: 10.1002/alz.70905.

Donanemab in early symptomatic Alzheimer's disease: results from the TRAILBLAZER-ALZ 2 long-term extension

Zimmer JA, Sims JR, Evans CD, Nery ESM, Wang H, Wessels AM, Tronchin G, Sato S, Raket LL, Andersen SW, Sapin C, Paget MA, Gueorguieva I, Ardayfio P, Khanna R, Brooks DA, Matthews BR, Mintun MA; Alzheimer’s Disease Neuroimaging Initiative.

J Prev Alzheimers Dis. 2026 Feb;13(2):100446. doi: 10.1016/j.tjpad.2025.100446. Epub 2025 Dec 1.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias